(Q30667146)

26 June 2017

1 reference

title

A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data (English)

1 reference

26 June 2017

1 reference

J S Kennedy

1

1 reference

26 June 2017

F P Bymaster

2

1 reference

26 June 2017

L Schuh

3

1 reference

26 June 2017

D O Calligaro

4

1 reference

26 June 2017

G Nomikos

5

1 reference

26 June 2017

C C Felder

6

1 reference

26 June 2017

M Bernauer

7

1 reference

26 June 2017

B J Kinon

8

1 reference

26 June 2017

R W Baker

9

1 reference

26 June 2017

D Hay

10

1 reference

26 June 2017

H J Roth

11

1 reference

26 June 2017

M Dossenbach

12

1 reference

26 June 2017

C Kaiser

13

1 reference

26 June 2017

C M Beasley

14

1 reference

26 June 2017

J H Holcombe

15

1 reference

26 June 2017

M B Effron

16

1 reference

26 June 2017

A Breier

17

1 reference

26 June 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

International Journal of Geriatric Psychiatry

26 June 2017

published in

1 reference

26 June 2017

volume

16 Suppl 1

1 reference

26 June 2017

page(s)

S33-61

1 reference

Neuroleptic-induced akathisia: a review

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Potential role of muscarinic agonists in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Prejudices in pharmacology and pharmacotherapy. The so-called anticholinergic effect of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Factors associated with low body mass index and weight loss in nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Atypical antipsychotics and cardiovascular risk in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Novel 5-HT2-like receptor mediates neurogenic relaxation of the guinea-pig proximal colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Radioreceptor binding profile of the atypical antipsychotic olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Drug treatment as a cause of falls in old age. A review of the offending agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Acute confusional states during treatment with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

The muscarinic M(5) receptor: a silent or emerging subtype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Functional role of M2 muscarinic receptors in the guinea pig ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Placebo effect and randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Cardiovascular Health Risks Related to Overweight

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Effect of amantadine on weight gain during olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Weight change and diabetes incidence: findings from a national cohort of US adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Peripheral glucose metabolism in human hyperprolactinaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Alpha 1-adrenoceptors: subtypes, signaling, and roles in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Population frequency distribution of non-high-density lipoprotein cholesterol (Third National Health and Nutrition Examination Survey [NHANES III], 1988-1994).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

How to measure the QT interval--what is normal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Mood stabilization and weight loss with topiramate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Is hypercholesterolemia a risk factor and should it be treated in the elderly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Histamine H(1) receptors in patients with Alzheimer's disease assessed by positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

The binding of [3H]mepyramine to histamine H1 receptors in guinea-pig brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

The Framingham Study: ITS 50-year legacy and future promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Malnutrition in institutionalized elderly: how and why?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

The Comparative Peripheral Anticholinergic-Like Adverse Event Profiles of Olanzapine and Risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Psychotropic drugs, diabetes and chronic mental patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Drug effects on active immobility responses: what they tell us about neurotransmitter systems and motor functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Weight gain among schizophrenic patients treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Clozapine-induced weight gain: prevalence and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Extrapyramidal signs in patients with probable Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Undernutrition in the elderly population living at home in the community: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Cost of treating heart failure in an Irish teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Comparison of WHO and ADA criteria for diagnosis of glucose status in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Drug-induced orthostatic hypotension in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Atypical antipsychotics and hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Diabetes trends in the U.S.: 1990-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Worsening of motor features of parkinsonism with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Causes of weight loss in a community nursing home

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Measurement of the QT interval and the risk associated with QTc interval prolongation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Muscarinic receptor subtypes — pharmacological, molecular biological and therapeutical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Effects of chronic risperidone on central noradrenergic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Associations of subclinical cardiovascular disease with frailty

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Neuroleptic malignant syndrome: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Fatal cardiac event following initiation of risperidone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Effects of age on energy expenditure and substrate oxidation during experimental underfeeding in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Sustained response to open-label venlafaxine in drug-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Torsades de Pointes associated with intravenous haloperidol in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Zolmitriptan: a review of its use in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Pharmacologic treatment of diabetes in long-term care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Tolerability of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Glycaemia and insulinaemia in elderly European subjects (70-75 years).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

A prospective study of outcome from protein-energy malnutrition in nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Phenothiazines and Diabetes in Hospitalized Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Evaluation and management of cardiac arrhythmias in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Employment grade differences in cause specific mortality. A 25 year follow up of civil servants from the first Whitehall study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Drug-induced orthostatic hypotension in the elderly: avoiding its onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Orthostatic blood pressure control and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Management of the adverse effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

Ketoacidosis as a side-effect of clozapine: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1099-1166%28200112%2916%3A1%2B%3C%3A%3AAID-GPS571%3E3.0.CO%3B2-5

10.1002/1099-1166(200112)16:1+<::AID-GPS571>3.0.CO;2-5

21 January 2018

Identifiers

DOI

1 reference

26 June 2017

1 reference